Spirax-Sarco Engineering PLC

Board/Management Information • Jan 16, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 3041N

Spirax-Sarco Engineering PLC

16 January 2019

16th January 2019

CHANGE OF DIRECTOR DETAILS

In accordance with the Listing Rule requirement to give notice of changes in directorships held by current directors (LR 9.6.14 (2)), Clive Watson, Senior Independent Director and Non-Executive Director of Spirax‑Sarco Engineering plc, has announced his forthcoming retirement from Spectris plc no later than 1st April 2019.

Enquiries:

Andy Robson, General Counsel

Tel:  01242 535276

About Spirax Sarco

Spirax-Sarco Engineering plc comprises two world-leading businesses, Spirax Sarco for steam and electrical thermal energy solutions and Watson-Marlow Fluid Technology Group for niche peristaltic pumps and associated fluid path technologies.  Spirax Sarco provides a broad range of fluid control and electrical process heating products, engineered packages, site services and systems expertise for a diverse range of industrial and institutional customers.  The business helps its end users to improve production efficiency, reduce energy costs, water usage and emissions, improve product quality and enhance the safety of their operations.  Watson-Marlow Fluid Technology Group offers the ideal solution for a wide variety of demanding fluid path applications with highly accurate, controllable and virtually maintenance free pumps and associated technologies.  The Group is headquartered in Cheltenham, England, has strategically located manufacturing plants around the world and employs over 7,400 people, of whom over 1,600 are direct sales and service engineers.  Its shares have been listed on the London Stock Exchange since 1959 (symbol: SPX).

Further information can be found at www.spiraxsarcoengineering.com

LEI  213800WFVZQMHOZP2W17

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

RDNLLFLRLTIRLIA